Phase IIIB, Open-label, Multi-Center Study of the Efficacy and Safety of Rigosertib Administered as 72-hour Continuous Intravenous Infusions in Patients with Myelodysplastic Syndrome with Excess Blasts Progressing On or After Azacitidine or Decitabine
ID Number 13-1409Principal Investigator(s)
Lewis R Silverman
Department(s) or Division(s)
Hematology and Medical Oncology
The purpose of this study is to evaluate the safety and effectiveness of an experimental drug called rigosertib when it is given to people with MDS. Rigosertib is currently being tested in other clinical research studies. An experimental drug is not approved by the United States Food and Drug Administration (FDA) for use except in research studies. Rigosertib is currently being tested in other clinical research studies.
Rigosertib is being studied as a new potential anticancer drug and as potential treatment for myelodysplasia. Although the mechanism of action of rigosertib is not fully known, it is thought to kill cancer cells by two different actions: it stops the tumor cells from dividing and growing, and it blocks the proteins involved in cell division, causing cells to die.
Recruiting Patients: No